• Home
  • Adalid Sciences
6
Oct
2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
stand 8S76
Book a meeting

Adalid Sciences

About Adalid Sciences

Adalid Sciences develops next-generation lipid nanoparticles (LNPs) for RNA and DNA therapeutics. Founded in 2024 as an IOCB Prague spin-off and backed by BTL Group.
LNP performance depends on the whole composition, not just the ionizable lipid. We combine proprietary ionizable lipids with lipid-polymer conjugates that replace PEG-lipid entirely, and compositions customizable for multi-cargo delivery, prolonged circulation or targeting — backed by a library of preclinical LNPs and in-house high-throughput assembly instrumentation.
Partners come to us for difficult targets and PEG liabilities — via licensing or fee-for-service.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
    stand 8S76
  • Country/Region:
    Czech Republic
  • Founded:
    2024
  • On CPHI since:
    2026
  • Employees:
    25 - 49
Company types
Start-up
Primary activities
Biopharmaceutical
Chemical Development
Contract Research Organisation
Laboratory, Analytical, Biotechnology Equipment
Packaging & drug delivery
Pharmaceutical Company (innovator finished products)
Contact info
Show contact info Hide contact info

Products from Adalid Sciences (4)

  • Lipid nanoparticles for nucleic acids delivery - ionizable lipids

    Product Lipid nanoparticles for nucleic acids delivery - ionizable lipids

    Our ionizable-lipid libraries cover flexible and also conformationally constrained structures across conventional and new topologies, giving us precise control over LNP design for particular payloads and indications. Adalid's technology is backed by extensive intellectual property right...
  • Lipid nanoparticles for nucleic acids delivery - outer shell stabilizers

    Product Lipid nanoparticles for nucleic acids delivery - outer shell stabilizers

    Our libraries of lipid-polymer conjugates span diverse proprietary LNP stabilizers that tune particle properties and enable modular attachment of targeting ligands (e.g., antibodies and alternatives). Adalid's technology is backed by extensive intellectual property.
  • Lipid nanoparticles: ready-to-use optimized formulations

    Product Lipid nanoparticles: ready-to-use optimized formulations

    Adalid builds LNPs from libraries of ionizable lipids (flexible/constrained), helper lipids/sterols, and click-ready polymer-lipid stabilizers for ligand attachment. Our semi automated, high-throughput assembly platform delivers data-driven structure–performance maps, rapidly optimizing...
  • Optimization of lipid nanoparticles (LNPs) for nucleic acid delivery

    Product Optimization of lipid nanoparticles (LNPs) for nucleic acid delivery

    Adalid builds LNPs from libraries of ionizable lipids (flexible/constrained), helper lipids/sterols, and click-ready polymer-lipid stabilizers for ligand attachment. Our semi-automated, high-throughput assembly platform delivers data-driven structure-performance maps...